Growth hormone polypeptides and methods of making and using same
The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.
1. An isolated fusion protein, comprising a growth hormone (GH) that is at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein said growth hormone is linked to an extended recombinant polypeptide (XTEN) of at least 100 to about 3000 amino acids residues, wherein the XTEN is characterized in that:
(a) at least 80% the XTEN sequence consist of non-overlapping sequence motifs, wherein:
(i) each sequence motif has 12 to 36 amino acid residues, and
(ii) each motif consist of 4 to 6 types of amino acids selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P); and
(b) the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes more than 90% of the total amino acid residues of the XTEN sequence; and
wherein the XTEN comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 29-58.
2. The isolated fusion protein of claim 1 , wherein the growth hormone is a human growth hormone.
3. The isolated fusion protein of claim 1 , wherein each motif has 12 to 14 amino acid residues.
4. The isolated fusion protein of claim 1 , wherein the sequence of any two contiguous amino acid residues in any one sequence motif does not occur more than twice in the sequence motif.
5. The isolated fusion protein of claim 1 , wherein the content of any one amino acid type in the full-length XTEN does not exceed 30%.
6. The isolated fusion protein of claim 1 , wherein the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes at least 95% of the total amino acid residues of the XTEN sequence.
7. The isolated fusion protein of claim 1 , wherein the sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues at least 99% of the total amino acid residues of the XTEN sequence.
8. The isolated fusion protein of claim 1 , wherein the XTEN sequence comprises at least 400 to about 1000 amino acids residues.
9. The isolated fusion protein of claim 1 , wherein the XTEN sequence comprises at least 100 to about 200 amino acids residues.
10. The isolated fusion protein of claim 1 , wherein the XTEN sequence contains no three contiguous amino acids that are identical unless the amino acids are serine residues.
11. The isolated fusion protein as in any one of claims 1 , 8 , and 9 , further comprising a second XTEN sequence.
12. The fusion protein of claim 1 , wherein the fusion protein has a longer terminal half-life when administered to a subject compared to the corresponding GH that lacks the XTEN when administered to a subject at a comparable molar dose.
13. The fusion protein of claim 1 , wherein the fusion protein stimulates production of IGF-1 in a subject.
14. The isolated fusion protein of claim 1 , wherein the growth hormone peptide and the XTEN is linked via a spacer, wherein the spacer sequence comprises between 1 to about 50 amino acid residues.
15. A pharmaceutical composition comprising the isolated fusion protein of claim 1 , and a pharmaceutically acceptable carrier.
16. The isolated protein of claim 1 that is configured according to formula I:
(XTEN) x -GH-(XTEN) y , (I)
wherein independently for each occurrence:
(a) x is either 0 or 1; and
(b) y is either 0 or 1, wherein x+y≧1.
17. The isolated fusion protein of claim 1 , wherein the XTEN is fused to the growth hormone on an N- or C-terminus of the growth hormone.
18. The isolated fusion protein as in any one of claims 1 , 8 , 9 , and 17 , wherein the XTEN sequence is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs:63, 66-67, 69-77, and 851.
19. The isolated fusion protein as in claim 11 , wherein the XTEN sequence is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs:63, 66-67, 69-77, and 851.
20. The pharmaceutical composition of claim 15 formulated for subcutaneous administration.
21. A method of treating a growth-hormone related condition in a subject, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 15 or 20 , wherein the growth-hormone related condition is selected from growth-hormone deficiency, Turner's Syndrome, Prader-Willi Syndrome, idiopathic short stature, AIDS wasting, multiple sclerosis, Crohn's disease, ulcerative colitis, and muscular dystrophy.
22. The method of claim 21 , wherein the pharmaceutical composition is administered subcutaneously.
23. The method of claim 21 , wherein the pharmaceutical composition is administered less frequently in comparison to the corresponding growth hormone that lacks said XTEN or said first and second polypeptide.
24. The method of claim 21 , wherein a therapeutic effect is a measured parameter selected from IGF-1 concentrations, IGFBP3 concentration, height velocity, lean body mass, total body fat, trunk fat, response to insulin challenge, rate of division of chondrocytes, chondrocyte numbers, bone density, bone growth, and increase in epiphyseal plate width.